Evidence map›Paper›PMID 36660546›Full record

ArticleFrontiers in immunology2022

A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy.

He Li, Ke Zhou, Kaiyue Wang, Hui Cao, Wantao Wu, Zeyu Wang, Ziyu Dai, Shi Chen, Yun Peng, Gelei Xiao and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

He LiThe Animal Laboratory Center, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Ke ZhouSchool of Medicine, Hunan Normal University, Changsha, China.
Kaiyue WangThe Animal Laboratory Center, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Hui CaoBrain Hospital of Hunan Province, The Second People's Hospital of Hunan Province, Changsha, China.
Wantao WuNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zeyu WangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Ziyu DaiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Shi ChenSchool of Medicine, Hunan Normal University, Changsha, China.
Yun PengNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Gelei XiaoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Peng LuoDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zaoqu LiuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou, Zhengzhou, China.
Quan ChengDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Hao ZhangDepartment of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Central South University · CNHunan Cancer Hospital · CNHunan Normal University · CNChongqing Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNHunan University of Traditional Chinese Medicine · CNSouthern Medical University · CNXiangya Hospital Central South University · CNZhujiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: CD161 has been linked to the appearance and development of various cancers. Methods: The mutation map and the variation of CNVs and SNVs of CD161 were displayed according to cBioportal and GSCALite. We also evaluated the pathway enrichment and drug sensitivity of CD161 according to GSCALite. We performed a single-cell sequencing analysis of cancer cells and T cells in melanoma. The cell communication patterns related to CD161 were further explored. Multiplex immunofluorescence staining of tissue microarrays was used to detect the association between CD161 expression and macrophages and T cells. Results: A high CD161 level was related to neoantigens expression, pathway enrichment, and drug sensitivity. In addition, single-cell sequencing analysis showed that CD161 was mainly expressed in T cells, M1 and M2 Macrophages, neoplastic, microglial cells, neurons, and cancer cells in many tumor types. Further study on pseudotime trajectories and functional annotation of CD161 proved the critical role of CD161 in tumor progression and T cell immunity in melanoma. Multiplex immunofluorescence revealed that CD161 is closely correlated with the immune infiltration of T cells and macrophages in multiple cancers. In addition, high CD161 expression predicted a favorable immunotherapy response. Conclusion: CD161 is involved in the immune infiltration of T cells and macrophages and might be a promising target for tumor immunotherapy.

Indexed as

MelanomaTumor MicroenvironmentBiomarkersCell CommunicationHumansImmunotherapyBiomarkersCD161immunotherapymacrophagesmutationpan-cancerprognosisT cells

Identifiers

PMID36660546
PMCPMC9844218
OpenAlexW4313527202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.